GLOW Peptide for Skin & Hair: What the Research Shows by Component

Reviewed by Thomas Okafor, Peptide Chemist · Last reviewed October 16, 2026

No study has tested the GLOW blend on skin or hair. What exists is research on its three ingredients one at a time: small human studies of GHK-Cu creams, animal wound studies of BPC-157, and animal and human wound work on thymosin beta-4, the parent protein of TB-500.

That makes “GLOW peptide skin” research a set of separate findings, and each finding carries its own study type. This guide labels every result 🧪 lab, 🐭 animal or 👤 human, and keeps the topical cosmetic evidence apart from the research blend. Like every research peptide covered on this site, GLOW is for laboratory use only and isn’t meant for people to consume; our Medical Disclaimer sets out the details.

Three Things “GLOW for Skin” Can Mean

“GLOW for skin” can refer to three different products: the GLOW research vial, which combines GHK-Cu, BPC-157 and TB-500, cosmetic creams and serums containing GHK-Cu, or skincare simply marketed with the word “glow.” Only the second has human skin studies behind its main ingredient.

1. The research blend. A freeze-dried vial of three peptides, sold for laboratory research only. No skin or hair study has used it.
2. Copper peptide cosmetics. Serums and creams listing GHK-Cu, often as “copper tripeptide-1” on the ingredient label. These are applied to skin, and the human studies discussed below used products like these.
3. “Glow” branding. Skincare called glow serums or glow peptides may contain different peptides, or none, and the word itself is a marketing term with no fixed formula.

Search results and AI summaries often blend all three together. A study of a copper peptide cream says nothing about a research vial, and a “glow serum” may contain no GHK-Cu. The FDA’s guide to whether a product is a cosmetic, a drug or both explains why intended use decides how a product is regulated.

What’s in GLOW, and Which Components Appear in Skin Research

GLOW’s 70 mg vial is five parts GHK-Cu (50 mg) to one part each of BPC-157 and TB-500 (10 mg of each). All three appear in skin research, though in very different ways: GHK-Cu in human topical and lab studies, BPC-157 in animal burn and wound models, and TB-500’s parent protein in wound studies.

Recipes differ from seller to seller, and the batch certificate of analysis is the record for any one vial. Our GLOW peptide guide covers the formula in more detail.

GHK-Cu in Skin Research

GHK-Cu is a copper-bound tripeptide found naturally in human plasma and studied for skin since the 1970s. Human data come from a handful of short cream and serum trials, lab studies show fibroblasts making more collagen around it, and wound studies in rats and rabbits found more collagen forming in the injured area.

Human Topical Studies

👤 The clinical evidence for GHK-Cu comes from small cosmetic trials, summarized by Loren Pickart, who first isolated GHK, and Anna Margolina in a 2018 review. Findings they describe include:

• Skin density. A 12-week facial cream study in 71 women reported denser, thicker skin and fewer visible fine lines.
• Collagen. In a thigh-skin comparison, GHK-Cu cream raised collagen in 70% of participants, with vitamin C (50%) and retinoic acid (40%) creams trailing.
• Eye area. Over 12 weeks, 41 women using a GHK-Cu eye cream saw better skin measures than those using placebo or vitamin K cream.

Most of these studies were small, short and connected to the compound’s commercial developers. The August 2026 review in Pharmaceutics by Mateescu and colleagues judged the lab and animal evidence consistent and the controlled human evidence thin. Its example was a 13-person study after laser resurfacing, where instrument-based skin measures didn’t favor GHK-Cu.

Lab and Animal Studies

🧪 In cultured human skin fibroblasts, GHK-Cu raised collagen and elastin production and increased decorin and glycosaminoglycans, molecules that organize collagen and hold water. In gene-expression databases, GHK altered the activity of thousands of human genes, which researchers read as a sign of broad signaling effects in cells.

🐭 In rats, collagen dressings carrying GHK raised collagen in wounds several-fold, and rabbit studies reported better wound contraction. A 2015 review in BioMed Research International collects these models.

Topical Cosmetic vs Research-Grade Peptide

Cosmetic GHK-Cu is a dilute ingredient in a cream designed for skin, regulated as a cosmetic. Research-grade GHK-Cu in GLOW is concentrated powder, sold for lab work, mixed with two other peptides. The human findings above come from the first context. They don’t describe GLOW, and they don’t carry over to other forms or routes. Our page on GHK-Cu skin research compares the two in depth.

BPC-157 and TB-500 in Wound-Repair Research

BPC-157 has been studied in rodent burn and wound models, where it was linked to faster wound closure. TB-500’s skin evidence mostly belongs to full thymosin beta-4, which sped wound closure in several animal models and was tested in phase 2 human trials as a skin gel for chronic ulcers.

BPC-157. 🐭 A 2001 mouse study in Burns applied BPC-157 cream to burn wounds and reported faster recovery of the burned skin. A 2015 rat study by Huang and colleagues found faster closure of alkali burns, and 🧪 in the same paper BPC-157 increased cell growth, migration and new vessel formation in culture. Both are animal or lab findings, with no human skin data behind them.

Full thymosin beta-4. 🐭 Rat skin wounds closed faster with Tβ4 in the 1999 work of Malinda and colleagues. Treadwell’s 2012 overview lists similar results in normal, steroid-exposed, diabetic and aged rodents. 👤 It also reports two phase 2 trials testing a Tβ4 gel on chronic leg and pressure ulcers; among patients whose ulcers closed, closure came close to a month earlier. The authors call Tβ4 “a multifunctional regenerative peptide important in dermal repair.”

TB-500. TB-500 is a seven-amino-acid fragment of Tβ4, and those trials used the whole protein. No skin study of TB-500 itself has been published.

GLOW and Hair: What the Studies Cover

Hair research related to GLOW’s ingredients is limited to lab and animal work: a copper tripeptide closely related to GHK-Cu lengthened human hair follicles in a dish, a copper peptide enlarged follicles in rats, and full thymosin beta-4 stimulated hair growth in rats and mice. No hair study of GLOW exists.

GHK-Cu and Hair-Follicle Research

The copper-peptide hair studies cited online often turn out to test relatives of GHK-Cu.

🧪 AHK-Cu, human follicles. Seoul National University researchers tested AHK-Cu, a copper tripeptide with alanine in place of GHK’s glycine, on human hair follicles kept alive in culture. Pyo and colleagues reported in 2007 that it lengthened follicles and increased growth of dermal papilla cells, the cells that direct follicle growth.

🐭 A copper-binding peptide in rats. In a 1993 report, Uno and Kurata described a copper-binding peptide, PC1031, enlarging hair follicles on the backs of fuzzy rats, with an effect they compared to topical minoxidil.

🐭 Full Tβ4. National Institutes of Health researchers found that thymosin beta-4 stimulated hair growth in normal rats and mice, partly by helping follicle stem cells move to the base of the follicle.

👤 One small clinical report tested copper peptides on scalps, though only in a combination with minoxidil and dutasteride, so the peptides’ own contribution can’t be separated.

What Isn’t Known

GLOW itself has never been tested on human hair growth, and neither have GHK-Cu as such, BPC-157 or TB-500. The closest evidence uses related copper peptides or the full Tβ4 protein, in dishes and rodents. Clinic before-and-after claims about hair can’t fill that space, because they lack comparison groups and verified product contents.

Skin & Hair Research Table by Component, Area and Study Type

GLOW vs KLOW in Skin Research

KLOW is GLOW with a fourth peptide, KPV (10 mg), a three-amino-acid fragment of alpha-MSH studied for inflammation signaling. For skin research, that adds a compound with lab and mouse inflammation data, though KPV has no human skin studies of its own.

🧪 and 🐭 KPV’s research centers on calming inflammatory signaling, mainly through NF-κB, in cell and mouse models. A 2008 review in Endocrine Reviews by Brzoska and colleagues covers alpha-MSH and its tripeptides, including findings in skin cells. GLOW leaves that piece out and keeps the collagen and repair side. Our pages on KLOW for skin research and side-by-side blend comparison set the blends next to each other, and our skin health research hub lists related compounds.

Limits of the Evidence

The skin and hair evidence for GLOW’s ingredients is limited by small samples, short timelines, industry funding and a reliance on animal and lab models. No study has tested the blend, and topical findings for GHK-Cu don’t carry over to other forms.

• Small and short. Each GHK-Cu skin trial involved a few dozen volunteers for three months at most.
• Funding. Many GHK-Cu studies come from researchers connected to its commercial development.
• Related molecules. Key hair data come from AHK-Cu, PC1031 or full Tβ4.
• Species. Rodent skin repairs itself and grows hair differently from human skin.
• Form. Topical cosmetic results don’t describe research powder in a mixed vial.
• No blend data. How the three peptides behave together on skin or hair is untested.

FAQs

Which peptides are studied in skin research?

GHK-Cu is the most studied, with small human topical trials plus lab and animal work. BPC-157 has been studied in rodent burn and wound models, and thymosin beta-4, TB-500’s parent protein, has animal wound data and phase 2 human gel trials. KPV, found in KLOW, has lab and mouse inflammation data.

Is the GHK-Cu in GLOW the same as in copper peptide serums?

It’s the same molecule, used in a very different context. Serums contain dilute GHK-Cu in a cosmetic base for skin. GLOW contains concentrated research-grade GHK-Cu combined with BPC-157 and TB-500 in one vial, sold only for laboratory research.

Has GLOW been studied for hair?

No. No study has tested GLOW on hair. Related research includes a lab study of the copper peptide AHK-Cu on human follicles, a rat study of a copper-binding peptide and rodent studies of full thymosin beta-4.

Is GLOW approved for cosmetic use?

No. GLOW is a lab-only research product, and none of its ingredients is FDA-approved as a drug. GHK-Cu is used in cosmetics, but that doesn’t extend to GLOW, which isn’t marketed or regulated as a cosmetic.

Where can I read about GLOW side effects?

Our upcoming GLOW side effects guide sorts the reported findings for each ingredient by study type. In the meantime, our BPC-157 side effects page covers the most-studied component.